Cyclic nucleotide compartmentalization: Contributions of phosphodiesterases and ATP-binding cassette transporters

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 231-253

  Cheepala, Satish ^a   Hulot, Jean Sebastien ^b   Morgan, Jessica A ^a   Sassi, Yassine ^d   Zhang, Weiqiang ^c   Naren, Anjaparavanda P ^c   Schuetz, John D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

cAMP; CFTR; efflux; export; MRP4

Indexed keywords

ABC TRANSPORTER; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; DIPYRIDAMOLE; MULTIDRUG RESISTANCE PROTEIN 4; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; TREQUINSIN; VARDENAFIL; ZAPRINAST; ZARDAVERINE;

CARDIOVASCULAR SYSTEM; CAVEOLA; CELL COMPARTMENTALIZATION; DIARRHEA; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CYCLIC AMP; CYCLIC GMP; HUMANS; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES;

EID: 84872226985     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134609     Document Type: Review

References (106)

1. Buxton IL, Brunton LL. 1983. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem. 258:10233-39
2. Jurevicius J, Fischmeister R. 1996.cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. USA 93:295-99
3. Dao KK, Teigen K, Kopperud R, Hodneland E, Schwede F, et al. 2006. Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. J. Biol. Chem. 281:21500-11
4. Tasken K, Aandahl EM. 2004. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 84:137-67
5. Rich TC, Fagan KA, Nakata H, Schaack J, Cooper DM, Karpen JW. 2000. Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMPdiffusion. J. Gen. Physiol. 116:147-61
6. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW. 2001. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc. Natl. Acad. Sci. USA 98:13049-54
7. Zaccolo M, Pozzan T. 2002. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711-15
8. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, et al. 2002. Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science 298:834-36
9. Omori K, Kotera J. 2007. Overview of PDEs and their regulation. Circ. Res. 100:309-27
10. Kleppisch T. 2009. Phosphodiesterases in the central nervous system. Handb. Exp. Pharmacol. 191:71-92
11. Brechler V, Pavoine C, Hanf R, Garbarz E, Fischmeister R, Pecker F. 1992. Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phosphodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein. J. Biol. Chem. 267:15496-501
12. Mery PF, Brechler V, Pavoine C, Pecker F, Fischmeister R. 1990. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345:158-61
13. Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechene P, et al. 2008. Spatiotemporal dynamics of β-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ. Res. 102:1091-100
14. Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S. 2006. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β1-adrenergic but locally confined β2-adrenergic receptormediated signaling. Circ. Res. 99:1084-91
15. Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, et al. 2006. PGE1 stimulation of HEK293 cells generatesmultiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J. Cell Biol. 175:441-51
16. Herget S, Lohse MJ,NikolaevVO. 2008. Real-time monitoring of phosphodiesterase inhibition in intact cells. Cell. Signal. 20:1423-31
17. Francis SH, Houslay MD, Conti M. 2011. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. Handb. Exp. Pharmacol. 204:47-84
18. Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, et al. 2000. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3): Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J. Biol. Chem. 275:38749-61
19. Bolger GB, McCahill A, Yarwood SJ, Steele MR, Warwicker J, Houslay MD. 2002. Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMPspecific phosphodiesterase, PDE4D5. BMC Biochem. 3:24
20. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, et al. 2001. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J. Biol. Chem. 276:11189-98
21. Osadchii OE. 2007. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc. Drugs Ther. 21:171-94
22. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, et al. 1999. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J. Biol. Chem. 274:11796-810
23. Huston E, BeardM,McCallum F, Pyne NJ, Vandenabeele P, et al. 2000. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3: consequences for altered intracellular distribution. J. Biol. Chem. 275:28063-74
24. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD. 2000. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131:811-19
25. Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, et al. 2002. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J. Biol. Chem. 277:28298-309
26. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, et al. 1994. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell Biol. 126:111-26
27. Patel HH, Murray F, Insel PA. 2008. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu. Rev. Pharmacol. Toxicol. 48:359-91
28. Jacobson K, Mouritsen OG, Anderson RG. 2007. Lipid rafts: at a crossroad between cell biology and physics. Nat. Cell Biol. 9:7-14
29. Nilsson R, Ahmad F, Sward K, AnderssonU,Weston M, et al. 2006. Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cell. Signal. 18:1713-21
30. Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, et al. 2007. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L294-303
31. Bender AT, Beavo JA. 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58:488-520
32. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, et al. 2000. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol. 59:347-56
33. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, et al. 2003. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64:533-46
34. Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, et al. 2010. Compartmentalized cyclic adenosine 3-,5-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol. Biol. Cell 21:1097-110
35. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, et al. 2003. β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi. Proc. Natl. Acad. Sci. USA 100:940-45
36. Baillie GS, Houslay MD. 2005. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr. Opin. Cell Biol. 17:129-34
37. Davoren PR, Sutherland EW. 1963. The effect of L-epinephrine and other agents on the synthesis and release of adenosine 3-,5-phosphate by whole pigeon erythrocytes. J. Biol. Chem. 238:3009-15
38. Sutherland EW, Rall TW. 1958. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232:1077-91
39. Barber R, Ray KP, Butcher RW. 1980. Turnover of adenosine 3-,5-monophosphate inWI-38 cultured fibroblasts. Biochemistry 19:2560-67
40. Brunton LL, Buss JE. 1980. Export of cyclic AMP by mammalian reticulocytes. J. Cycl. Nucleotide Res. 6:369-77
41. Campbell IL, Taylor KW. 1981. The effect of metabolites, papaverine, and probenecid on cyclic AMP efflux from isolated rat Islets of Langerhans. Biochim. Biophys. Acta 676:357-64
42. Doore BJ, Bashor MM, Spitzer N, Mawe RC, Saier MH Jr. 1975. Regulation of adenosine 3-:5-monophosphate efflux from rat glioma cells in culture. J. Biol. Chem. 250:4371-72
43. Finnegan RB, Carey GB. 1998. Characterization of cyclic AMP efflux from swine adipocytes in vitro. Obes. Res. 6:292-98
44. Rindler MJ, Bashor MM, Spitzer N, Saier MH Jr. 1978. Regulation of adenosine 3-:5-monophosphate efflux from animal cells. J. Biol. Chem. 253:5431-36
45. Billiar TR,Curran RD, Harbrecht BG, Stadler J,Williams DL, et al. 1992. Association between synthesis and release of cGMP and nitric oxide biosynthesis by hepatocytes.Am. J. Physiol. Cell Physiol. 262:C1077-82
46. Sager G. 2004. Cyclic GMP transporters. Neurochem. Int. 45:865-73
47. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, et al. 1999. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-51
48. Chen ZS, Lee K, Kruh GD. 2001. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276:33747-54
49. van Aubel RAMH, Smeets PHE, Peters JGP, Bindels RJM, Russel FGM. 2002. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13:595-603
50. Wielinga PR, van derHeijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. 2003. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278:17664-71
51. Rall TW, Sutherland EW. 1958. Formation of a cyclic adenine ribonucleotide by tissue particles. J. Biol. Chem. 232:1065-76
52. Linton KJ, Holland IB, eds. 2011. The ABC Transporters of Human Physiology and Disease: Genetics and Biochemistry of ATP Binding Cassette Transporters. Hackensack, NJ: World Sci.
53. Besnard V, Matsuzaki Y, Clark J, Xu Y,Wert SE, et al. 2010. Conditional deletion of Abca3 in alveolar type II cells alters surfactant homeostasis in newborn and adult mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 298:L646-59
54. Molday RS, Zhong M, Quazi F. 2009. The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim. Biophys. Acta 1791:573-83
55. Kosters A, Karpen SJ. 2008. Bile acid transporters in health and disease. Xenobiotica 38:1043-71
56. Borst P, Elferink RO. 2002. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:537-92
57. Gottesman MM, Ambudkar SV. 2001. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 33:453-58
58. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55:3-29
59. Oldham ML, Davidson AL, Chen J. 2008. Structural insights into ABC transporter mechanism. Curr. Opin. Struct. Biol. 18:726-33
60. Hohl M, BriandC,Grutter MG, Seeger MA. 2012. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nat. Struct. Mol. Biol. 19:395-402
61. Annilo T, Chen ZQ, Shulenin S, Costantino J, Thomas L, et al. 2006. Evolution of the vertebrate ABC gene family: analysis of gene birth and death. Genomics 88:1-11
62. Dano K. 1972. Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother. Rep. 56:701-8
63. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-62
64. Cole SPC, Bhardwaj G, Gerlach JH,Mackie JE, Grant CE, et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-54
65. Ernst R, Kueppers P, Stindt J, Kuchler K, Schmitt L. 2010. Multidrug efflux pumps: substrate selection in ATP-binding cassette multidrug efflux pumps-first come, first served? FEBS J. 277:540-49
66. Lee K, Klein-Szanto AJ, Kruh GD. 2000. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92:1934-40
67. Leggas M, Adachi M, Scheffer GL, SunD,Wielinga P, et al. 2004. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol. 24:7612-21
68. Morgan JA, Cheepala SB, Wang Y, Neale G, Adachi M, et al. 2012. Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice. J. Biol. Chem. 287:14456-66
69. Hoque MT, Cole SPC. 2008. Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. Cancer Res. 68:4802-9
70. Hoque MT, Conseil G, Cole SPC. 2009. Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. Biochem. Biophys. Res. Commun. 379:60-64
71. Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, et al. 2007. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131:940-51
72. Sassi Y, Lipskaia L, Vandecasteele G, Nikolaev VO, Hatem SN, et al. 2008. Multidrug resistanceassociated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J. Clin. Investig. 118:2747-57
73. Sellers ZM, Naren AP, Xiang Y, Best PM. 2012. MRP4 and CFTR in the regulation of cAMP and β-adrenergic contraction in cardiac myocytes. Eur. J. Pharmacol. 681:80-87
74. Jedlitschky G, Burchell B, Keppler D. 2000. The multidrug resistance protein 5 functions as an ATPdependent export pump for cyclic nucleotides. J. Biol. Chem. 275:30069-74
75. Shipp LE, Hamdoun A. 2012. ATP-binding cassette (ABC) transporter expression and localization in sea urchin development. Dev. Dyn. 241:1111-24
76. Krishnamurthy P, Schuetz JD. 2006. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46:381-410
77. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the sidepopulation phenotype. Nat. Med. 7:1028-34
78. Zahir T, Chen YF, MacDonald JF, Leipzig N, Tator CH, Shoichet MS. 2009. Neural stem/progenitor cells differentiate in vitro to neurons by the combined action of dibutyryl cAMP and interferon-γ. Stem Cells Dev. 18:1423-32
79. Asai J, Takenaka H, Katoh N, Kishimoto S. 2006. Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J. Investig. Dermatol. 126:1159-67
80. de Wolf CJ, Yamaguchi H, van der Heijden I,Wielinga PR,Hundscheid SL, et al. 2007.cGMPtransport by vesicles from human and mouse erythrocytes. FEBS J. 274:439-50
81. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, et al. 2007. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 67:6965-72
82. Ahlstrom M, Lamberg-Allardt C. 1999. Regulation of adenosine 3-,5-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: role of cAMP-phosphodiesterase and cAMP efflux. Biochem. Pharmacol. 58:1335-40
83. Barber R, Butcher RW. 1981. The quantitative relationship between intracellular concentration and egress of cyclic AMP from cultured cells. Mol. Pharmacol. 19:38-43
84. Fehr TF, Dickinson ES, Goldman SJ, Slakey LL. 1990. Cyclic AMP efflux is regulated by occupancy of the adenosine receptor in pig aortic smooth muscle cells. J. Biol. Chem. 265:10974-80
85. Brunton LL, Mayer SE. 1979. Extrusion of cyclic AMP from pigeon erythrocytes. J. Biol. Chem. 254:9714-20
86. Russel FGM, Koenderink JB, Masereeuw R. 2008. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29:200-7
87. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, et al. 2002. Analysis ofmethotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:3144-50
88. Hara Y, Sassi Y, Guibert C, Gambaryan N, Dorfm̈ uller P, et al. 2011. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J. Clin. Investig. 121:2888-97
89. Sassi Y, Abi-Gerges A, Fauconnier J, MougenotN,Reiken S, et al. 2012. Regulation of cAMPhomeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 26:1009-17
90. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. 1994. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. Cell Physiol. 267:C1405-13
91. Sassi Y, Hara Y, Lompre AM, Hulot JS. 2009. Multi-drug resistance protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. Cell Cycle 8:962-63
92. CooperDM. 2005. Compartmentalization of adenylate cyclase and cAMP signalling. Biochem. Soc. Trans. 33:1319-22
93. Jackson EK, Raghvendra DK. 2004. The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu. Rev. Physiol. 66:571-99
94. Hetman JM, Soderling SH, Glavas NA, Beavo JA. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. USA 97:472-76
95. Lugnier C. 2006. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109:366-98
96. Gresser U, Gleiter CH. 2002. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur. J. Med. Res. 7:435-46
97. Ashikaga T, Strada SJ, Thompson WJ. 1997. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells. Biochem. Pharmacol. 54:1071-79
98. Qiu Y, Kraft P, Lombardi E, Clancy J. 2000. Rabbit corpus cavernosum smoothmuscle shows a different phosphodiesterase profile than human corpus cavernosum. J. Urol. 164:882-86
99. Liu S, Veilleux A, Zhang L, Young A, Kwok E, et al. 2005. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4Dphosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 314:846-54
100. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, et al. 2001. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 13:282-90
101. Francis SH, Sekhar KR, Ke H, Corbin JD. 2011. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. Handb. Exp. Pharmacol. 200:93-133
102. Gibson A. 2001. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil. Eur. J. Pharmacol. 411:1-10
103. Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB. 1998. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273:15559-64
104. Schudt C, Winder S, Eltze M, Kilian U, Beume R. 1991. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl. 34:379-402
105. Reid G, Wielinga P, ZelcerN,DeHaas M, Van Deemter L, et al. 2003. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteinsMRP4 and MRP5.Mol. Pharmacol. 63:1094-103
106. Chen Z-S, Guo Y, Belinsky M, Kotova E, Kruh G. 2005. Transport of bile acids, sulfated steroids, estradiol 17-β-D-glucuronide and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. 67:545-57